ExpreS2ion Biotechnologies

Sidste chance: Seminar for institutionelle investorer: Fokus på danske aktier Husk at HC Andersen Capital inviterer til et eksklusivt seminar for institutionelle investorer torsdag d. 16. januar 2025. På dagen vil en række spændende selskaber præsentere deres virksomhed, og der bliver rig mulighed for at netværke med andre investorer. 📅 Dato: 16. januar 2025 ⏰ Tid: 08.00 - 17.00 🎤 Program: 🕒 8:30 - 8:55: GreenMobility A/S – CEO Kasper Gjedsted 🕘 9:00 - 9:25: FluoGuide A/S – CEO Morten Albrechtsen 🕤 9:30 - 9:55: Folketrygdfondet – CEO Kjetil Houg 🕙 10:00 - 10:25: ExpreS2ion Biotechnologies – CEO Bent Frandsen 🕥 10:30 - 10:55: GomSpace – CEO Carsten Drachmann 🕚 11:00 - 11:25: BioPorto A/S – Niels Høy Nielsen 🕦 11:30 - 11:55: NNIT – CEO Pär Fors 🍴 12:00 - 12:25: Lunch Break 🕧 12:30 - 12:55: Donkey Republic – CEO Niels Henrik Rasmussen 🕐 13:00 - 13:25: Ascelia Pharma AB – Dep. CEO Julie Waras Brogren 🕜 13:30 - 13:55: Curasight – CEO Ulrich Krasilnikoff 🕑 14:00 - 14:25: Copenhagen Capital – CEO Rasmus Greis 🕑 14.30 - 14.55: MapsPeople – CEO Morten Brøgger 🕑 15.00 - 15.25: BactiQuant A/S – CEO Morten Miller 👥 Målgruppe: Seminaret er målrettet institutionelle investorer fra både Danmark, Sverige og Norge, herunder pensionskasser, investeringsforeninger, fonde, family offices, private banking-afdelinger, samt analytikere og sales teams fra investeringsbanker. 📩 Tilmelding og deltagelse: Kontakt os for deltagelse – pladserne er begrænsede! Tue Østergaard: tue@hcandersencapital.dk Jesper Thomsen: jesper@hcandersencapital.dk Mie Halse: mie@hcandersencapital.dk Vi glæder os til at byde jer velkommen til en inspirerende dag fyldt med indsigt og netværk!

📢 Join ExpreS2ion at the HC Andersen Capital Institutional Investor Seminar! On 16 January 2025, our CEO, Bent Frandsen, will present at HC Andersen Capital’s Institutional Investor Seminar in Copenhagen. This is an exciting opportunity to hear about ExpreS2ion’s innovative technology platform and development pipeline, including our novel therapeutic breast cancer vaccine, ES2B-C001, which recently received Clinical Trial Application (CTA) approval for a Phase I clinical trial. 🎯 Event Details: 📍 Location: Copenhagen, Denmark 🕑 Date and Time: 16 January 2025 This seminar is a unique chance to connect with Nordic institutional investors and learn more about how ExpreS2ion is advancing cutting-edge solutions in oncology and infectious disease. 📩 Interested in attending? Institutional investors can contact HC Andersen Capital directly for participation details. #ExpreS2ion #Biotech #ClinicalTrials #HER2 #BreastCancer #Oncology #Vaccines

We're #hiring a new Laboratory Technician in Hørsholm Municipality, Capital Region of Denmark. Apply today or share this post with your network.

🎉 Reflecting on a remarkable 2024 at ExpreS2ion Biotechnologies! This year has been filled with key milestones that bring us closer to our mission of developing innovative vaccines for infectious diseases and cancer: ✅ Submission of our CTA in August and securing approval in December to initiate our Phase I clinical safety trial—a significant step forward for our lead therapeutic breast cancer vaccine program, ES2B-C001. ✅ Progression across our preclinical pipeline, strengthening our position in infectious disease vaccine development. ✅ Signing a term sheet with the Serum Institute of India in October, setting the foundation for impactful collaboration. To hear more about our journey and what lies ahead in 2025, watch the CEO interview below. 🎥 These achievements are a testament to the hard work, innovation, and dedication of our entire team and partners. 🚀 Wishing you all a joyful holiday season and a successful New Year! 🌟 #Vaccines #Biotechnology #Innovation #Teamwork #VaccinesWork #VaccinesSaveLives #2024Achievements #LookingAheadTo2025 HC Andersen Capital

Exciting Progress in Malaria Vaccine Development 🌍 Publication of Phase IIb Trial Data for RH5.1 Malaria Vaccine 🌍 Conducted by researchers at the University of Oxford, this double-blind, randomized, controlled Phase IIb trial in children demonstrates the potential of the RH5.1/Matrix-M blood-stage malaria vaccine candidate. Kudos to the dedicated researchers and teams involved in this groundbreaking work! ExpreS2ion Biotechnologies is proud to support the antigen manufacturing platform with #ExpreS2. See also: https://lnkd.in/dgumwBif #Malaria #VaccineDevelopment #GlobalHealth #ClinicalTrials #Biotechnology

 🌟 Exciting news: ExpreS2ion Biotechnologies announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer! 🎉   Read the news here: https://lnkd.in/dUgu2ZaX   #Biotech #BreastCancerResearch #Innovation #ExpreS2ionBiotechnologies #BreastCancerVaccine #CancerVaccine #FightBreastCancer #CancerAwareness #CancerTreatment #HER2Positive #ClinicalTrials #MedicalResearch #VaccinesSaveLives 

🚀 Unlocking the Future of HER2-Positive Cancer Treatment with ES2B-C001 At ExpreS2ion Biotech, we are making strides in addressing the significant unmet medical need for HER2-positive cancer treatment with our groundbreaking therapeutic vaccine, ES2B-C001. With a targeted approach and compelling preclinical data, we’re poised to make a real difference in the lives of patients. 🖥️ Hear directly from our CEO, Bent Frandsen! In two recent investor presentations, Bent Frandsen outlines the potential of ES2B-C001 and our integrated development plan (iDP) to bring this innovative treatment closer to reality. Check out the presentations here: 🔗 Watch the videos and download the presentations: https://lnkd.in/dZegjVv4 -Biostock Life Science Summit (Nov 21, 2024) -Analysguiden Stora Aktiedagarna (Nov 27, 2024) These talks highlight: ✔️ Compelling preclinical data: 100% survival in treated animals. ✔️ Targeting a €27B global market with 7.2% CAGR. ✔️ Our Phase I clinical trial application in Austria, with a decision expected imminently. We are grateful for the ongoing support of our investors and partners in building a future of transformative treatments. Let’s advance together! #Biotech #Innovation #HER2Positive #CancerResearch #Vaccines #BreastCancer

#ICYMI: Having clinical Phase III-validated our vaccine platform in COVID-19, we focus on the treatment of breast cancer. Last week in Lund, our CEO Bent Frandsen presented ExpreS2ion Biotechnologies and our therapeutic breast cancer vaccine ES2B-C001 (HER2-VLP) at the Biostock Life Science Summit hosted by BioStock - Connecting Innovation and Capital. If you couldn’t join us live, have a look at this video-link: https://lnkd.in/dHi4W9VT #VaccinesSaveLives #VaccinesWork #BreastCancerResearch #LifeSciences #InvestorConference 🎗 🔬 👍

🌟 Catch up on ExpreS2ion Biotech’s Q3 2024 Highlights! 🌟 We’re pleased to share the recording of last week's Q3 report webcast, where our CEO Bent Frandsen and CFO Keith Alexander provide an in-depth update on our achievements, ongoing initiatives, and financial performance. This session highlights the tangible progress we’re making to deliver on our long-term vision and value-driving milestones. 🧬📈 🎧 While the video feed faced a technical glitch, the full audio recording is available along with the presentation slides, allowing you to follow along seamlessly. 💡 Key Highlights Include: 1.     Submission of the clinical trial application for our pioneering breast cancer vaccine candidate 2.     Issuance of a new patent, further bolstering and extending our intellectual property portfolio 3.     Updates on our malaria vaccine programs, which provide further validation of the ExpreS2 protein production system At ExpreS2ion, we are committed to creating long-term value by reaching critical milestones and engaging actively with investors, partners, and stakeholders. Biotech innovation takes time, but each step brings us closer to achieving significant breakthroughs. We appreciate your continued support and interest in our journey. https://lnkd.in/dZegjVv4

📢 Looking forward to a glimpse into our innovative vaccines for a healthier world 🚀 This week in Lund, Sweden, our CEO Bent Frandsen presents ExpreS2ion Biotechnologies at the event Biostock Life Science Summit hosted by BioStock - Connecting Innovation and Capital. See the program and register here: https://lnkd.in/db3-5i3T #VaccinesSaveLives #VaccinesWork #BreastCancerResearch #LifeSciences #InvestorConference 🎗 🔬 👍